lexiara

preamble_14

(4) orphan medicinal products eligible for incentives should be easily and unequivocally identified; it seems most appropriate to achieve this result through the establishment of an open and transparent Community procedure for the designation of potential medicinal products as orphan medicinal products;

· All articles ·

Source: EUR-Lex (Cellar) · retrieved 2026-11-21 · Text as adopted (Official Journal); later amendments are not incorporated in this text.